News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

George Zahrah

Articles by George Zahrah

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

ByErika P. Hamilton, MD,Rinath M. Jeselsohn,Sara A. Hurvitz, MD,Dejan Juric,Hyo S Han,Melinda L. Telli, MD,George Zahrah,Rita Nanda, MD,Yuanyuan Zhang,Weiwei Tan,Elizabeth Duperret,Eric Zhi,Cecile Mather,Anne F. Schott, MD

August 10th 2024

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath M. Jeselsohn,Pamela N. Munster, MD,Eric Zhi,Elizabeth Duperret,Cecile Mather,Erika P. Hamilton, MD,Hyo S Han

August 4th 2024

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Could Scorpion Venom Component Play a Role in Glioblastoma Management?

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC

What Were The Most Impactful GU Oncology Data From ESMO 2025?

FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications

© 2025 MJH Life Sciences^®

All rights reserved.